<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lorlatinib: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lorlatinib: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Lorlatinib: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="119621" href="/d/html/119621.html" rel="external">see "Lorlatinib: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F52098020"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Lorbrena</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F53273098"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Lorbrena</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F52090722"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Anaplastic Lymphoma Kinase Inhibitor;</li>
<li>
                        Antineoplastic Agent, Tyrosine Kinase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F52105297"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3ac928cc-a5fe-47d5-847f-e5abed320440">Non–small cell lung cancer, metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer, metastatic (ALK-positive):</b>
<b>Oral:</b> 100 mg once daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29074098','lexi-content-ref-31669155','lexi-content-ref-33207094']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29074098','lexi-content-ref-31669155','lexi-content-ref-33207094'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Missed doses:</b></i>If a dose is missed, administer the missed dose unless the next dose is due within 4 hours. Do not administer 2 doses at the same time to make up for a missed dose. If vomiting occurs, do not administer an additional dose; continue with the next scheduled dose.</p></div>
<div class="block dora drugH1Div" id="F52105299"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Kidney function estimated using the Cockcroft-Gault formula.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl 30 to 89 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl 15 to &lt;30 mL/minute: Reduce dose to 75 mg once daily.</p>
<p style="text-indent:-2em;margin-left:2em;">End-stage renal impairment requiring dialysis: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F52105300"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (total bilirubin ≤ ULN with AST &gt; ULN <b>or</b> total bilirubin &gt;1 to 1.5 times ULN with any AST): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment (total bilirubin ≥1.5 to 3 times ULN with any AST) or severe impairment (total bilirubin &gt;3 times ULN with any AST): There are no dosage adjustments provided in the manufacturer's labeling (has not been established).</p></div>
<div class="block dot drugH1Div" id="F52105301"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Lorlatinib Dose Reduction Levels for Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Dose level</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Lorlatinib dose</b></p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial (usual) dose</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">100 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">First dose reduction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">75 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Second dose reduction</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">50 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Subsequent</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue lorlatinib if unable to tolerate 50 mg once daily.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Lorlatinib Recommended Dose Modifications for Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Adverse reaction</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Severity</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Lorlatinib dose modification</b></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup>Control BP prior to initiating lorlatinib.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<i>Cardiovascular toxicity</i></p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">Atrioventricular (AV) block</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Second-degree AV block</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold lorlatinib until PR interval is &lt;200 msec, and then resume lorlatinib at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">First occurrence of complete AV block</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold lorlatinib until either pacemaker is placed or PR interval is &lt;200 msec. If a pacemaker is placed, resume lorlatinib at the same dose. If no pacemaker is placed, resume lorlatinib at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Recurrent complete AV block</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Place pacemaker or permanently discontinue lorlatinib.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">Hypertension<sup>a</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3 (systolic BP [SBP] ≥160 mm Hg or diastolic BP [DBP] ≥100 mm Hg; medical intervention indicated; &gt;1 antihypertensive medication, or more intensive therapy than previously used indicated)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold lorlatinib until hypertension has recovered to ≤ grade 1 (SBP &lt;140 mm Hg and DBP &lt;90 mm Hg), then resume lorlatinib at the same dose. If grade 3 hypertension recurs, withhold lorlatinib until recovery to ≤ grade 1, then resume at a reduced dose. If hypertension cannot be adequately controlled with optimal medical management, permanently discontinue lorlatinib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 4 (life-threatening consequences, urgent intervention indicated)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold lorlatinib until recovery to ≤ grade 1, then resume at a reduced dose or permanently discontinue lorlatinib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Recurrent grade 4 hypertension</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Permanently discontinue lorlatinib.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<i>CNS effects</i></p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">CNS effects (eg, seizures, psychotic effects, changes in cognitive function, mood [including suicidal ideation], speech, mental status, sleep)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 1</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Continue lorlatinib at the same dose or withhold until recovery to baseline. Resume lorlatinib at the same dose or at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 2 or 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold dose until resolved to grade 0 or 1, then resume lorlatinib at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Permanently discontinue lorlatinib.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<i>Metabolic effects</i></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hyperglycemia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3 (fasting serum glucose &gt;250 mg/dL despite optimal antihyperglycemic therapy or grade 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold lorlatinib until hyperglycemia is appropriately controlled, then resume at the next lower dose. If hyperglycemia cannot be adequately controlled with optimal medical management, permanently discontinue lorlatinib.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Hyperlipidemia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 4 hypercholesterolemia or grade 4 hypertriglyceridemia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold lorlatinib until recovery of hypercholesterolemia and/or hypertriglyceridemia to ≤ grade 2 and then resume lorlatinib at the same dose. If severe hypercholesterolemia and/or hypertriglyceridemia recurs, resume lorlatinib at a reduced dose. Hyperlipidemia may require initiation (or increased doses) of lipid-lowering agents.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<i>Pulmonary effects</i></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Treatment-related interstitial lung disease (ILD)/pneumonitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Any grade</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Immediately withhold lorlatinib if ILD/pneumonitis is suspected. Permanently discontinue lorlatinib for ILD/pneumonitis of any severity.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<i>Other adverse reactions</i></p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">
<b></b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 1 or 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Continue lorlatinib at the same dose or at a reduced dose.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Withhold lorlatinib until symptoms resolve to ≤ grade 2 or baseline, then resume lorlatinib at a reduced dose.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F52105298"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F52105118"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (11%), edema (56% to 57%), hypertension (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (11% to 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercholesterolemia (91% to 96%), hyperglycemia (48% to 52%), hyperkalemia (21%), hypertriglyceridemia (90% to 95%), hypoalbuminemia (33% to 36%), hypomagnesemia (21%), hypophosphatemia (21%), increased amylase (20% to 22%), increased gamma-glutamyl transferase (52%), weight gain (24% to 38%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (15% to 17%), diarrhea (21% to 22%), increased serum lipase (24% to 28%), nausea (15% to 18%), vomiting (12% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (48% to 52%; grade 3/4: 2% to 5%), lymphocytopenia (22% to 23%; grades 3/4: 3%), prolonged prothrombin time (25%), thrombocytopenia (23%; grade 3/4: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (28% to 44%), increased serum alkaline phosphatase (23% to 24%), increased serum aspartate aminotransferase (37% to 48%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cognitive dysfunction (21% to 27%), dizziness (11% to 16%), fatigue (19% to 26%), headache (17% to 18%), mood disorder (16% to 23%), peripheral neuropathy (34% to 47%; grade 3/4: 2% to 3%), sleep disorder (10% to 11%), speech disturbance (7% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (19% to 23%), back pain (13% to 15%), increased creatine phosphokinase in blood specimen (39%), limb pain (13% to 17%), myalgia (15% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance (15% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (81%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (16% to 18%), dyspnea (20% to 27%), upper respiratory tract infection (11% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (12% to 17%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Mental status changes (1%), psychotic reaction (3% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (7%), pneumonia (3% to 7%), respiratory failure (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrioventricular block</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pulmonary disease, pneumonitis</p></div>
<div class="block coi drugH1Div" id="F52090725"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Concomitant use of strong CYP3A inducers.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to lorlatinib or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F52105283"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: PR interval prolongation and atrioventricular block may rarely occur in patients receiving lorlatinib, including grade 3 events. Some patients required pacemaker placement.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: CNS effects (including seizures, psychotic effects/changes and cognitive function, mood [including suicidal ideation], speech, mental status, and sleep changes) may occur in patients receiving lorlatinib. Overall, CNS effects occurred in just over half of patients receiving lorlatinib. Cognitive effects occurred in nearly one-third patients who received lorlatinib (at any dose) in one study; a small percentage of these events were severe (grade 3 or 4). Mood effects occurred in nearly one-fourth of patients; severe events occurred rarely. Speech effects, hallucinations, and mental status changes have also been reported, including rare severe events. Seizures have been observed, sometimes in conjunction with other neurologic findings. Changes in sleep have also been reported. The median time to initial onset of any CNS effect was 1.4 months (range: 1 day to 3.4 years).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperglycemia: Hyperglycemia has been reported, including grade 3 or 4 events. The median time to onset of hyperglycemia was 4.8 months (range: 1 day to 2.9 years).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperlipidemia: Serum cholesterol and triglycerides increases may occur in patients receiving lorlatinib. Grade 3 or 4 total cholesterol and triglyceride elevations have been reported. The median time to onset (for both hypercholesterolemia and hypertriglyceridemia) was 15 days. A majority of patients with hypercholesterolemia and hypertriglyceridemia required initiation of lipid-lowering medications, usually at ~17 days after lorlatinib initiation. Initiate lipid-lowering agents (or increase the dose) in patients with hyperlipidemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertension: Hypertension may occur, including grade 3 and 4 events. The median time to onset of hypertension was 6.4 months (range: 1 day to 2.8 years). Control BP prior to lorlatinib initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Severe or life-threatening pulmonary adverse reactions consistent with interstitial lung disease (ILD)/pneumonitis may rarely occur with lorlatinib, including grades 3 and 4 events. Promptly evaluate new or worsening respiratory symptoms indicative of ILD/pneumonitis (eg, dyspnea, cough, fever).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• ALK positivity: Select patients for the treatment of metastatic non-small cell lung cancer based on the presence of ALK positivity in tumor specimens. Information on approved tests for detection of ALK gene rearrangements may be found at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2FCompanionDiagnostics&amp;token=8RYIFfyLhIBYEqeX7m6uPDm4uqqqOExUfjxBFpDlDD1g0WtQtQ%2FQ%2FpH5amr9brPprwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=119539" target="_blank">https://www.fda.gov/CompanionDiagnostics</a>.</p></div>
<div class="block foc drugH1Div" id="F52098021"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lorbrena: 25 mg, 100 mg</p></div>
<div class="block geq drugH1Div" id="F52098019"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F52184946"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Lorbrena Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $284.79</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $854.38</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F53273099"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lorbrena: 25 mg, 100 mg</p></div>
<div class="block adm drugH1Div" id="F52105303"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer at the same time each day, with or without food. Swallow intact tablets whole; do not chew, crush, or split; do not ingest tablets that are broken, cracked, or otherwise not intact.</p></div>
<div class="block hazard drugH1Div" id="F52105285"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Lorlatinib may cause reproductive toxicity, teratogenicity, genotoxicity, and has a structural/toxicity profile similar to existing hazardous agents.</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block use drugH1Div" id="F52090724"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Non-small cell lung cancer, metastatic (ALK-positive):</b> Treatment of metastatic non-small cell lung cancer in adults whose tumors are ALK-positive (as detected by an approved test).</p></div>
<div class="block mst drugH1Div" id="F52105278"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Lorlatinib may be confused with alectinib, brigatinib, ceritinib, crizotinib, erlotinib, lapatinib, larotrectinib, lenvatinib, loratadine, lorazepam, lornafarnib.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its lists of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F52160974"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Induces</b> CYP2B6 (weak), CYP2C9 (weak), CYP3A4 (moderate), P-glycoprotein/ABCB1</p></div>
<div class="block dri drugH1Div" id="F52160971"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abemaciclib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Abemaciclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abiraterone Acetate: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Abiraterone Acetate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Acalabrutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: Lorlatinib may decrease the serum concentration of Acetaminophen. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Afatinib: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Afatinib.  Management: Increase the afatinib dose by 10 mg as tolerated in patients requiring chronic coadministration of P-gp inducers with afatinib. Reduce afatinib dose back to the original afatinib dose 2 to 3 days after discontinuation of the P-gp inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALfentanil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ALfentanil.  Management: If concomitant use of alfentanil and moderate CYP3A4 inducers is necessary, consider dosage increase of alfentanil until stable drug effects are achieved. Monitor patients for signs of opioid withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AmLODIPine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: Hypertension-Associated Agents may enhance the hypertensive effect of Androgens. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Antihepaciviral Combination Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Inducers of CYP3A4 (Moderate) and P-glycoprotein may decrease the serum concentration of Apixaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apremilast: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Apremilast. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Aprepitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ARIPiprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ARIPiprazole Lauroxil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Artemether and Lumefantrine. Specifically, concentrations of dihydroartemisinin (DHA), the active metabolite of artemether may be decreased. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Artemether and Lumefantrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Atogepant.  Management: For treatment of episodic migraine, the recommended dose of atogepant is 30 mg once daily or 60 mg once daily when combined with CYP3A4 inducers. When used for treatment of chronic migraine, use of atogepant with CYP3A4 inducers should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Atorvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avacopan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Avacopan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avanafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Avanafil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avapritinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Avapritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Axitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Axitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bedaquiline: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Bedaquiline. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bedaquiline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belumosudil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Belumosudil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzhydrocodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Benzhydrocodone. Specifically, the serum concentrations of hydrocodone may be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berotralstat: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Berotralstat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bortezomib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bosutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Brexpiprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Brigatinib.  Management: Avoid concurrent use of brigatinib with moderate CYP3A4 inducers when possible. If combined, increase the daily dose of brigatinib in 30 mg increments after 7 days of treatment with the current brigatinib dose, up to maximum of twice the dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: CYP2B6 Inducers (Weak) may decrease the serum concentration of BuPROPion. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of BusPIRone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capivasertib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Capivasertib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capmatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Capmatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cariprazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Celiprolol: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Cladribine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clarithromycin.  Management: Consider alternative antimicrobial therapy for patients receiving a CYP3A4 inducer. Drugs that enhance the metabolism of clarithromycin into 14-hydroxyclarithromycin may alter the clinical activity of clarithromycin and impair its efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clindamycin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobimetinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cobimetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Codeine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Copanlisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Copanlisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Crizotinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Crizotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May enhance the hepatotoxic effect of Lorlatinib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lorlatinib. Management: Avoid use of lorlatinib with moderate CYP3A4 inducers. If such a combination must be used, increase lorlatinib to 125 mg daily. Monitor for reduced lorlatinib efficacy and consider closer monitoring of AST, ALT, and bilirubin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May enhance the hepatotoxic effect of Lorlatinib. CYP3A4 Inducers (Strong) may decrease the serum concentration of Lorlatinib.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Lorlatinib. Management: Avoid use of lorlatinib with strong CYP3A4 inhibitors. If the combination cannot be avoided, reduce the lorlatinib dose from 100 mg once daily to 75 mg once daily, or from 75 mg once daily to 50 mg once daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with P-glycoprotein inducers whenever possible.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daclatasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Daclatasvir.  Management: Increase the daclatasvir dose to 90 mg once daily if used with a moderate CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dapsone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Daridorexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darolutamide: Inducers of CYP3A4 (Moderate) and P-glycoprotein may decrease the serum concentration of Darolutamide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasabuvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dasabuvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: CYP3A4 Inducers (Moderate) may increase the serum concentration of Dasatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deflazacort: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Deflazacort. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Delavirdine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of DexAMETHasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: CYP3A4 Inducers (Moderate) may decrease the serum concentration of DiazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dienogest: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DilTIAZem: CYP3A4 Inducers (Moderate) may decrease the serum concentration of DilTIAZem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Disopyramide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doravirine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Doravirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): CYP3A4 Inducers (Moderate) may decrease the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of DroNABinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dronedarone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Duvelisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Duvelisib.  Management: Avoid if possible. If used, on day 12 of combination increase duvelisib from 25 mg twice daily to 40 mg twice daily or from 15 mg twice daily to 25 mg twice daily. Resume prior duvelisib dose 14 days after stopping moderate CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dydrogesterone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dydrogesterone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Edoxaban.  Management: Avoid coadministration of edoxaban and P-glycoprotein (P-gp) inducers if possible. If concomitant use is required, be aware the edoxaban efficacy may be decreased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elacestrant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elbasvir and Grazoprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Eliglustat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elvitegravir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Entrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Erdafitinib.  Management: Dose modifications of erdafitinib may be required. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Erlotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Etoposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Etoposide Phosphate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Everolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exemestane: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Exemestane. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fedratinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Fedratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felodipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Felodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: CYP3A4 Inducers (Moderate) may decrease the serum concentration of FentaNYL. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexofenadine: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Fexofenadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Finerenone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluconazole: May increase the serum concentration of Lorlatinib. Management: Avoid use of lorlatinib with fluconazole whenever possible. If the combination cannot be avoided, reduce the lorlatinib dose from 100 mg once daily to 75 mg once daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Fosamprenavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Fosaprepitant. Specifically, CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite aprepitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosnetupitant: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Fosnetupitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostamatinib: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Fostamatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fruquintinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Fruquintinib.  Management: Avoid this combination when possible. If combined, continue the same fruquintinib dose, but monitor for reduced fruquintinib efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: Inducers of CYP3A4 (Moderate) and P-glycoprotein may decrease the serum concentration of Futibatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganaxolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ganaxolone.  Management: Avoid concomitant use of ganaxolone and moderate CYP3A4 inducers whenever possible. If combined, consider increasing the dose of ganaxolone, but do not exceed the maximum recommended daily dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Gefitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemigliptin: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Gemigliptin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Gemigliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Gepirone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: Inducers of CYP3A4 (Moderate) and P-glycoprotein may decrease the serum concentration of Gilteritinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glasdegib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Glasdegib.  Management: Avoid use of glasdegib and moderate CYP3A4 inducers whenever possible. If combined, increase glasdegib dose from 100 mg daily to 200 mg daily or from 50 mg daily to 100 mg daily. Resume previous glasdegib dose 7 days after discontinuation of the inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">GuanFACINE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of GuanFACINE.  Management: Increase extended-release guanfacine dose by up to double when initiating guanfacine in patients taking CYP3A4 inducers or if initiating a CYP3A4 inducer in a patient already taking extended-release guanfacine. Monitor for reduced guanfacine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Hormonal Contraceptives.  Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a moderate CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROcodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Hydrocortisone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrexafungerp: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ibrexafungerp. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ibrutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Imatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Indinavir.  Management: Consider avoiding the combination of indinavir and moderate CYP3A4 inducers whenever possible due to the risk for decreased indinavir concentrations, reduced efficacy, and development of resistance. If combined, monitor for indinavir treatment failure.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan Products: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, concentrations of SN-38 may be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isavuconazonium Sulfate: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inducers (Moderate) may decrease isavuconazole serum concentrations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isradipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Isradipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Istradefylline: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Istradefylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixazomib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ixazomib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketamine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ketamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lapatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Larotrectinib.  Management: Double the larotrectinib dose if used together with a moderate CYP3A4 inducer. Following discontinuation of the moderate CYP3A4 inducer, resume the previous dose of larotrectinib after a period of 3 to 5 times the inducer's half-life.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ledipasvir: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Ledipasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin with moderate CYP3A4 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin with P-glycoprotein/ABCB1 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin (Intravenous): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lefamulin (Intravenous).  Management: Avoid concomitant use of lefamulin (intravenous) with moderate CYP3A4 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin (Intravenous): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Lefamulin (Intravenous).  Management: Avoid concomitant use of lefamulin (intravenous) with P-glycoprotein/ABCB1 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lemborexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenacapavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lenacapavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Leniolisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lercanidipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lercanidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Letermovir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levamlodipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Levamlodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Levomethadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LinaGLIPtin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of LinaGLIPtin.  Management: Strongly consider using an alternative to any P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lonafarnib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lovastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lumateperone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lurasidone.  Management: Monitor for decreased lurasidone effects if combined with moderate CYP3A4 inducers and consider increasing the lurasidone dose if coadministered with a moderate CYP3A4 inducer for 7 or more days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macitentan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Macitentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maraviroc: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice/day, but only if not receiving a strong CYP3A4 inhibitor. Not recommended for pediatric patients not also receiving a strong CYP3A4 inhibitor. Contraindicated in patients with CrCl less than 30 mL/min.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maribavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Maribavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mavacamten. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mefloquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Meperidine. Specifically, concentrations of normeperidine, the CNS stimulating metabolite, may be increased. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Meperidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MethylPREDNISolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of MethylPREDNISolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mianserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Midostaurin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of MiFEPRIStone.  Management: Avoid combined use in patients treated for Cushing's disease. When used for pregnancy termination, mifepristone efficacy may be reduced and an alternative pregnancy termination procedure may be warranted. Ensure a follow-up assessment after combined use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirodenafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mirodenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: May enhance the hepatotoxic effect of Lorlatinib. Lorlatinib may decrease the serum concentration of Mitapivat. Mitapivat may decrease the serum concentration of Lorlatinib. Management: Coadministration of lorlatinib and mitapivat should be avoided. If combined, increase the lorlatinib dose to 125 mg once daily and titrate mitapivat beyond 50 mg twice daily based on hemoglobin, if needed, to a maximum dose of 100 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mobocertinib: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Mobocertinib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mobocertinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Naloxegol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Netupitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Netupitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nevirapine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nevirapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of NIFEdipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nilotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilvadipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nilvadipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nintedanib: Inducers of CYP3A4 (Moderate) and P-glycoprotein may decrease the serum concentration of Nintedanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nisoldipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olaparib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olutasidenib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olutasidenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Omaveloxolone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orelabrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Orelabrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osimertinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Osimertinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of OxyCODONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): CYP3A4 Inducers (Moderate) may decrease the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): CYP3A4 Inducers (Moderate) may decrease the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pacritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Palbociclib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palovarotene: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Palovarotene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of PAZOPanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pemigatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pemigatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Perampanel.  Management: Increase perampanel starting dose to 4 mg/day if used with moderate CYP3A4 inducers. Increase perampanel dose by 2 mg/day no more than once weekly based on response and tolerability. Dose adjustments may be needed if the inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimavanserin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pimavanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Piperaquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pirtobrutinib.  Management: Avoid concomitant use if possible. If combined, if the current pirtobrutinib dose is 200 mg once daily, increase to 300 mg once daily. If current pirtobrutinib dose is 50 mg or 100 mg once daily, increase the dose by 50 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PONATinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of PONATinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pralsetinib.  Management: If this combo cannot be avoided, increase pralsetinib dose from 400 mg daily to 600 mg daily; from 300 mg daily to 500 mg daily; and from 200 mg daily to 300 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Praziquantel: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Praziquantel.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for reduced praziquantel efficacy. If possible, stop the moderate CYP3A4 inducer 2 to 4 weeks before praziquantel initiation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PrednisoLONE (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of PrednisoLONE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PredniSONE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of PredniSONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pretomanid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: Lorlatinib may decrease the serum concentration of Propacetamol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of QUEtiapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of QuiNIDine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of QuiNINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quizartinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Quizartinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ranolazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Regorafenib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Regorafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix: Inducers of CYP3A4 (Moderate) and P-glycoprotein may decrease the serum concentration of Relugolix. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Relugolix, Estradiol, and Norethindrone: Inducers of CYP3A4 (Moderate) and P-glycoprotein may decrease the serum concentration of Relugolix, Estradiol, and Norethindrone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ribociclib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Rilpivirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Rimegepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ripretinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ripretinib.  Management: Avoid this combination if possible. If concomitant use is required, increase ripretinib to 150 mg twice daily. Decrease ripretinib to 150 mg once daily 14 days after stopping a moderate CYP3A4 inducer. Monitor patients for ripretinib response and toxicity<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of RisperiDONE. CYP3A4 Inducers (Moderate) may decrease the serum concentration of RisperiDONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ritlecitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Inducers of CYP3A4 (Moderate) and P-glycoprotein may decrease the serum concentration of Rivaroxaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast (Systemic): CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Roflumilast (Systemic). CYP3A4 Inducers (Moderate) may decrease the serum concentration of Roflumilast (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rolapitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Rolapitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Samidorphan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Samidorphan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Selpercatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Selumetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertraline: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sertraline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sildenafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sildenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Sirolimus (Protein Bound). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sofosbuvir: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Sofosbuvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: May enhance the hypertensive effect of Hypertension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sonidegib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sonidegib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of SORAfenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sparsentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUFentanil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of SUFentanil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of SUNItinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Suvorexant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tadalafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tadalafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamoxifen: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tamoxifen. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tasimelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tazemetostat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, sirolimus concentrations may be decreased. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Temsirolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenofovir Alafenamide: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Tenofovir Alafenamide.  Management: Consider alternatives to the use of P-gp inducers with tenofovir alafenamide. If combined, monitor for reduced tenofovir alafenamide concentrations and efficacy, and for the development of resistance.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tetrahydrocannabinol and Cannabidiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezacaftor and Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tezacaftor and Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiotepa: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Thiotepa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ticagrelor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tivozanib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tivozanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tofacitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tolvaptan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Toremifene. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Toremifene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Trabectedin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of TraZODone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 100 mg and second dose (if needed) of 100 mg when used with a moderate CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Upadacitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Valbenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vandetanib: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Vandetanib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vandetanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vemurafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Venetoclax. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verapamil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Verapamil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilazodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vilazodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): CYP2C9 Inducers (Weak) may decrease the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voclosporin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vonoprazan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vonoprazan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vorapaxar. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vortioxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxelotor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voxelotor.  Management: Avoid concomitant use of voxelotor and moderate CYP3A4 inducers. If unavoidable, increase the voxelotor dose to 2,000 mg once daily. For children ages 4 to less than 12 years, weight-based dose adjustments are required. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxilaprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voxilaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zaleplon: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zaleplon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zanubrutinib.  Management: Avoid this combination if possible. If coadministration of zanubrutinib and a moderate CYP3A4 inducer is required, increase the zanubrutinib dose to 320 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zolpidem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zopiclone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zuranolone. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F52105281"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status in females of reproductive potential prior to initiating therapy. Females of reproductive potential should avoid pregnancy and use an effective nonhormonal method of contraception during treatment and for at least 6 months after the final lorlatinib dose. Male patients with female partners of reproductive potential should use effective contraception during treatment and for at least 3 months after the last lorlatinib dose.</p></div>
<div class="block pri drugH1Div" id="F52105280"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, lorlatinib may cause fetal harm if administered during pregnancy.</p></div>
<div class="block brc drugH1Div" id="F52105282"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if lorlatinib is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer does not recommend breastfeeding during therapy and for 7 days after the last lorlatinib dose.</p></div>
<div class="block mop drugH1Div" id="F52105305"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">ALK positivity (in tumor specimen). Monitor serum cholesterol and triglycerides (prior to initiating lorlatinib, at 1 and 2 months after lorlatinib initiation, and periodically thereafter); LFTs (as clinically indicated); fasting serum glucose (prior to initiating lorlatinib and periodically thereafter). Evaluate pregnancy status (prior to treatment in females of reproductive potential). Monitor ECG (prior to lorlatinib initiation and periodically thereafter) and BP (2 weeks after lorlatinib initiation and at least monthly thereafter). Monitor for signs/symptoms of CNS adverse events and interstitial lung disease/pneumonitis. Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p>
<p style="text-indent:-2em;margin-left:2em;">Additional cardiovascular monitoring: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017]; ESC [Lyon 2022]). Consider home BP monitoring; assess cholesterol profile every 3 to 6 months (ESC [Lyon 2022]).</p></div>
<div class="block pha drugH1Div" id="F52105287"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Lorlatinib is a reversible potent third generation tyrosine kinase inhibitor that targets ALK and ROS1; it is highly selective, overcomes known ALK resistance mutations, and penetrates the blood brain barrier (Shaw 2017). Lorlatinib has antitumor activity against multiple mutant forms of the ALK enzyme, including some mutations detected in tumors at the time of disease progression on crizotinib and other ALK inhibitors. Antitumor activity of lorlatinib is dose-dependent and correlates with inhibition of ALK phosphorylation. Lorlatinib also exhibits activity against TYK1, FER, FPS, TRKA, TRKB, TRKC, FAK, FAK2, and ACK.</p></div>
<div class="block phk drugH1Div" id="F52105288"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid (Shaw 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>ss</sub>: 305 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 66%; to plasma proteins.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily via CYP3A4 and UGT1A4, with minor contribution from CYP2C8, CYP2C19, CYP3A5, and UGT1A3.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 81%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 1.2 hours (range: 0.5 to 4 hours) following a single dose; 2 hours (range: 0.5 to 23 hours) at steady state.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine: 48% (&lt;1% as unchanged drug); feces: 41% (~9% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance (CL/F), mean: 11 L/hour (following a single 100 mg dose) and 18 L/hour at steady state.</p></div>
<div class="block phksp drugH1Div" id="F55583811"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Following a single 100 mg dose, AUC increased by 42% in subjects with severe renal impairment, compared to subjects with normal renal function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F53550961"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Lorbrena | Lorbrexen</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Tigify</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Lorbrena</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Lorbrena</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Lorlak</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Lorbriqua</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Lorbrena</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Lorbrena</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Lorbrena</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Lorbrena</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Lorbrena</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Lorbrena</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Lorbrena</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Lorviqua</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Lorbrena | Lorviqua</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Lorbrena</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorlatinib-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorlatinib-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Lorbrena (lorlatinib) [prescribing information]. New York, NY: Pfizer Labs; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lorbrena.1">
<a name="Lorbrena.1"></a>Lorbrena (lorlatinib) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J.</i> 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorlatinib-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33207094">
<a name="33207094"></a>Shaw AT, Bauer TM, de Marinis F, et al; CROWN Trial Investigators. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. <i>N Engl J Med</i>. 2020;383(21):2018-2029. doi:10.1056/NEJMoa2027187<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorlatinib-drug-information/abstract-text/33207094/pubmed" id="33207094" target="_blank">33207094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29074098">
<a name="29074098"></a>Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. <i>Lancet Oncol</i>. 2017;18(12):1590-1599.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorlatinib-drug-information/abstract-text/29074098/pubmed" id="29074098" target="_blank">29074098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31669155">
<a name="31669155"></a>Shaw AT, Solomon BJ, Chiari R, et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. <i>Lancet Oncol</i>. 2019;20(12):1691-1701. doi:10.1016/S1470-2045(19)30655-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lorlatinib-drug-information/abstract-text/31669155/pubmed" id="31669155" target="_blank">31669155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Accessed November 6, 2018.</div>
</li></ol></div><div id="topicVersionRevision">Topic 119539 Version 162.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
